Only one exceptional patient sample (patient #11) identified with unchanged and either upregulated transcription activity of SETD2, PBRM1, BAP1 and VHL, respectively, in his ccRCC sections. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.